At first glance, I didn't read it that way. Howeve

At first glance, I didn't read it that way. However, when you pointed it out, it became almost obvious. There is a lot here; you're right.

I read that they are doing fine with their old and trusty YAK line and don't feel like competing with YAK by pushing Dharmanol and T-Hydrocan which they say they are still perfecting.

YAK is their product line that pre-dates founding of Berkeley Bio, SK sub. That line is much more exclusively GoldNApel's line than Med Greens, would it not be? The licensing schedule for YAK might be more favorable to GoldNApel and the gross profit greater to GoldNApel. Follow the money?

Another thought. Is there a rift here? When iequity grabbed the IP in the AV matter, did that change any terms in licensing agreement to make it more favorable for GoldNApel to stay focused on their YAK line pursuant to sales?

Another thought. Is this their diplomatic way of saying Dharmanol and T-Hydrocan are not selling well and/or have not been received well so they will stay with YAK?

Finally, it wasn't signed. I wonder who wrote it.

"The new product lines we are developing, Dharmanol™ and T-Hydrocan™, are meant to “upgrade” the YAK capsule model to be more in line with the nutraceutical / pharmaceutical market, as opposed to the more casual approach ... Because we have the YAK Capsules available in hundreds of California dispensaries, we feel that we can take our time somewhat in perfecting our new offerings, because the market for them is being fulfilled with the YAK capsules currently, which generate substantial ongoing revenues, and have done so for about six years."